Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2005
06/15/2005EP1539971A1 Her-2/neu dna vaccine having anti-cancer activity
06/15/2005EP1539957A1 Novel diagnostic and therapeutic methods and reagents therefor
06/15/2005EP1539956A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF
06/15/2005EP1539934A2 Compositions comprising muscle progenitor cells and uses thereof
06/15/2005EP1539933A2 Methods of organ regeneration
06/15/2005EP1539931A1 Differentiation modulating agents and uses therefor
06/15/2005EP1539802A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
06/15/2005EP1539796A1 Anti-inflammatory or anti-allergic androstane complexes
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539742A1 Indole derivatives useful as histamine h3 antagonists
06/15/2005EP1539739A1 Piperidinyl compounds that selectively bind integrins
06/15/2005EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
06/15/2005EP1539727A2 Compounds, compositions, and methods
06/15/2005EP1539700A1 8-hydroxy quinoline derivatives
06/15/2005EP1539693A1 Cannabinoid receptor agonists
06/15/2005EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539662A1 Cannabinoid receptor ligands
06/15/2005EP1539282A2 Improved injection system
06/15/2005EP1539247A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
06/15/2005EP1539245A2 Methods and materials for treating human papillomavirus infections
06/15/2005EP1539242A2 A composition and method to augment and sustain neurotransmitter production
06/15/2005EP1539241A2 Method of controlling pharmacokinetics of immunomodulatory compounds
06/15/2005EP1539240A2 Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
06/15/2005EP1539222A1 Treatment for eye disorder
06/15/2005EP1539219A2 Affinity small molecules for the epo receptor
06/15/2005EP1539217A2 Methods for identification of compounds modulating insulin resistance
06/15/2005EP1539208A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
06/15/2005EP1539207A1 Treatment of cell proliferative disorders with chlorotoxin
06/15/2005EP1539202A1 Method for cancer therapy using herbal extracts
06/15/2005EP1539188A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
06/15/2005EP1539186A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
06/15/2005EP1539185A2 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate)
06/15/2005EP1539184A1 Estrogen replacement regimen
06/15/2005EP1539181A2 Method of treating lower urinary tract disorders
06/15/2005EP1539170A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
06/15/2005EP1539169A2 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
06/15/2005EP1539153A2 Therapeutic treatment for the metabolic syndrome and type 2 diabetes
06/15/2005EP1539149A2 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
06/15/2005EP1539147A1 Methods of treating microbial infections in humans and animals
06/15/2005EP1539144A2 Multistage formulation containing a biguanide and a thiazolidinedione derivative
06/15/2005EP1539142A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer s disease
06/15/2005EP1539137A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539136A2 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539134A2 Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539131A2 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
06/15/2005EP1539122A2 Aqueous 2,6-diisopropylphenol pharmaceutical compositions
06/15/2005EP1539120A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea
06/15/2005EP1538980A1 Devices and methodologies useful in body aesthetics
06/15/2005EP1538913A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/15/2005EP1538908A2 Novel substituted benzimidazole dosage forms and method of using same
06/15/2005EP1427842A4 Mid 9002, a human sulfatase family member and uses therefor
06/15/2005EP1411911A4 Beta-adrenergic blockade reversal of catabolism after severe burn
06/15/2005EP1408977B1 A combination therapy for the treatment of heart failure
06/15/2005EP1373240B1 Retinoid x receptor modulators
06/15/2005EP1341764B1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
06/15/2005EP1311259B1 Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent
06/15/2005EP1278530B1 Chemical modification of mammalian urine
06/15/2005EP1276496B1 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
06/15/2005EP1268519B1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
06/15/2005EP1259229B1 USE OF BENZO-THIENO[2,3-d]PYRIMIDINES HAVING PDE V INHIBITING ACTIVITY FOR THE TREATMENT OF ERECTILE DYSFUNCTION
06/15/2005EP1257277B1 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
06/15/2005EP1198255A4 Identification of compounds that modify transcriptional responses to hypoxia
06/15/2005EP1171121B1 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth
06/15/2005EP1165070B1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment
06/15/2005EP1114031B1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
06/15/2005EP1061923B1 Metal chelators for use in the treatment of alzheimer's disease
06/15/2005EP0979099B1 Use of lactoferin in the treatment of allergen induced disorders
06/15/2005EP0855915B1 Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases
06/15/2005CN1628179A Gene and protein relating to hepatocellular carcinoma
06/15/2005CN1628106A Salts of valsartan
06/15/2005CN1628104A Quinazolinone derivatives and their use as CB agonists
06/15/2005CN1627951A Compositions and method for prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
06/15/2005CN1627945A Quinoline derivatives as NPY antagonists
06/15/2005CN1626679A Methods for assessing and treating cancer
06/15/2005CN1626652A Method for accelerating quick growth of animals and method for improving quality of meat
06/15/2005CN1626552A Angiogenesis related molecules
06/15/2005CN1626244A Combination for treating skin disease
06/15/2005CN1626107A Pyrimidine nucleoside and pharmacy usage of pyrimidine nucleotide precursor
06/15/2005CN1206133C Infusion packet and its use
06/15/2005CN1205999C Liposone composition and method for administration of a radiosensitizer
06/15/2005CN1205994C Pulmonary delivery of active agents
06/15/2005CN1205935C Highly selective norepinephrine reuptake inhibitors and methods of using same
06/15/2005CN1205926C Agents for combating neospora spec
06/15/2005CN1205923C Liposome-entrapped topoisomerase inhibitors
06/15/2005CN1205921C Long acting injectable formulations contg. hydrogenated castor oil
06/14/2005US6906192 Processes for the preparation of acid derivatives useful as serine protease inhibitors
06/14/2005US6906175 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor.
06/14/2005US6906174 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
06/14/2005US6906106 Compositions for the skin comprising fibers and ubiquinones and methods of using the same
06/14/2005US6906082 Cholesteryl ester transfer protein inhibitor; anticholesterol agents, cardiovascular disorders; synergistic mixture
06/14/2005US6906081 For treatment of Alzheimer's disease, learning disabilities
06/14/2005US6906061 Therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic
06/14/2005US6906059 Administering cardioprotective amount of a benzazepin-N-acetic acid derivative for inhibiting or treating heart damage induced by a cardiotoxic medicamet in a mammal
06/14/2005US6906058 Prevent bile acid transportation; anticholesterol agents
06/14/2005US6906053 Antiarthritic agents; antiulcer agents; osteoporosis; antiinflammatory agents; antitumor and anticancer agents
06/14/2005US6906049 Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
06/14/2005US6906040 Method for reducing toxicity of combined chemotherapies
06/14/2005US6906038 Reducing side effects of radiation and chemotherapy, via the administration of an oral rehydration solution of sodium, potassium and citrate
06/14/2005US6906026 Methods for treating conditions associated with the accumulation of excess extracellular matrix
06/14/2005US6905855 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
1 ... 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 ... 1151